| Q1 Results, Healthcare Reforms Provide Pharma Opportunity to Downplay Expectations EP Vantage submits:The analysis of US health care reform’s damage to big pharma came thick and fast as companies reported first quarter earnings. The two biggest global pharmaceutical companies by sales in 2009 reported a combined $91m in negative first quarter effects from the law and smaller ones likewise reported millions of dollars in bottom-line impacts as the Medicaid program for the poor imposed a drug payment cut effective January 1, 2010.As its passage was fresh in the minds of investors and analysts, companies had little choice but to discuss how the law would affect their bottom lines, given that the legislation backdated its increase in the mandatory Medicaid rebates. But it is propitious timing for an industry that in recent times has taken a kicking from investors who see its innovative edge disappearing in a flurry of patent expiries in coming years. The reform law’s frontloading of cost onto big pharma certainly provides an opportunity to lower expectations, that can more easily be exceeded in the future.Complete Story » seekingalpha.com |
Nu Skin Keep Your Age a Mystery Contest - Video NU SKIN LAUNCHES GLOBAL CONTEST TO IDENTIFY NEW 'FRESH FACES' OF AGELOC feedproxy.google.com |
Clarient Achieves Profitability and Continues Growth Trajectory in the Second Quarter of 2010 (PR Newswire) Clarient, Inc. , a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the second quarter ended June 30, 2010. Â Second quarter 2010 net revenue was $28.7 million, a 21 percent increase over the $23.7 million net revenue in the 2009 second quarter and a sequential increase of nearly eight percent over the $26.6 million in the first quarter of 2010. Â us.rd.yahoo.com |
Gene-Altered Fish Closer to Approval The U.S. has moved closer to approving a lab-tweaked salmon that grows twice as fast as farmed fish and would become the first genetically modified animal to appear on American dinner plates. online.wsj.com |
BioClinica Appoints James W. Lovett to Its Board of Directors [Business Wire] - BioClinicaâ„¢, Inc., , a leading provider of clinical trial management services, today announced that it has appointed James W. Lovett to its Board of Directors, increasing the size of the Board to nine members. us.rd.yahoo.com |